A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma
- 1 January 1979
Abstract
Sixty‐seven patients with measurable colorectal carcinoma were randomized to receive two different schedules of Methyl CCNU, 5‐FU and Vincristine (MOF). The treatment schedule consisted of Methyl CCNU 150 mg/m2 po q 70 days, 5‐FU 300 mg/m2 iv for 5 consecutive days q 35 days, and Vincristine 1 mg/m2 IV q 35 days. The same total dose was used in each arm; in MOF A, the Methyl CCNU was given on day 1, while in MOF B, the Methyl CCNU was divided and given over 5 consecutive days. In MOF A, there was a 10% partial response rate and a 10% minor response rate. In MOF B, the partial response rate was 12% and the minor response rate was 21%. This difference is not statistically significant, but the patients in MOF B experienced less gastrointestinal toxicity (p <.001).This publication has 5 references indexed in Scilit:
- Methyl-CCNU in Malignant Melanoma – A Divided Dose Schedule of AdministrationOncology, 1977
- Fluorouracil, methyl-ccnu and vincristine in cancer of the colonCancer, 1976
- Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU.A southwest oncology group studyCancer, 1976
- Brief Communication: Therapy of Advanced Colorectal Cancer With a Combination of 5-Flourouracil, Methyl-l,3-cis(2-chlorethyl)-1-nitrosourea, and Vincristine2JNCI Journal of the National Cancer Institute, 1975
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataPublished by JSTOR ,1973